Global Oncology

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

More News

Dr. Azad on the Significance of the PROfound Trial in mCRPC

By Arun Azad, PhD

October 23rd 2020

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, of the University College Dublin

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

By Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

October 21st 2020

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

By Zarnie Lwin, MBBS, FRACP

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Patricia Pautier, MD, of Institut Gustave Roussy

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

By Patricia Pautier, MD

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

First-in-Human T-Cell Therapy Warrants Further Investigation in HCC

By Jessica Hergert

October 9th 2020

New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

By Nicole Concin, MD

October 7th 2020

Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

By Patricia Pautier, MD

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Bavituximab/Pembrolizumab Combo Is Active in Advanced Gastric/GEJ Cancer

By Caroline Seymour

October 6th 2020

The combination of bavituximab and pembrolizumab demonstrated synergistic antitumor activity and was well tolerated in patients with pretreated advanced gastric or gastroesophageal junction cancer.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

By Rebecca Kristeleit, BSc, PhD

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

By Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

By Alexander M. M. Eggermont, MD, PhD

September 30th 2020

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

By Manfred Welslau, MD

September 22nd 2020

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.